» Articles » PMID: 17684833

A Cost-utility Analysis of Adult Group Audiologic Rehabilitation: Are the Benefits Worth the Cost?

Overview
Date 2007 Aug 10
PMID 17684833
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to conduct a cost-utility analysis comparing two treatment approaches: (1) hearing aid use alone (HA) and (2) hearing aid use with short-term group postfitting audiologic rehabilitation (HA + AR). A total of 105 veterans, 67 males and 38 females, with at least a mild sensorineural hearing loss participated in this study. The SF-36V was administered to each participant before and after treatment. This instrument measures both mental component summary (MCS) scales and physical component summary (PCS) scales of quality of life. As a whole, the participants exhibited a statistically significant improvement in mean MCS scores pre- to postintervention, with average improvements of 1.4 and 3.0 points for the HA and HA + AR groups, respectively. With the use of the MCS scores, the results of a cost-utility analysis revealed that HA treatment cost $60.00 per quality-adjusted life year (QALY) gained, while HA + AR cost only $31.91 per QALY gained, making HA + AR the more cost-effective treatment.

Citing Articles

Service delivery approaches related to hearing aids in low- and middle-income countries or resource-limited settings: A systematic scoping review.

Dillard L, Der C, Laplante-Levesque A, Swanepoel D, Thorne P, McPherson B PLOS Glob Public Health. 2024; 4(1):e0002823.

PMID: 38266001 PMC: 10807760. DOI: 10.1371/journal.pgph.0002823.


U.S. Policy Considerations for Telehealth Provision in Audiology.

Jilla A, Arnold M, Miller E Semin Hear. 2021; 42(2):165-174.

PMID: 34381300 PMC: 8328556. DOI: 10.1055/s-0041-1731697.


The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review.

Daoud E, Caimino C, Akeroyd M, Norena A, Baguley D Pharmacoecon Open. 2021; 6(1):21-32.

PMID: 34213755 PMC: 8807799. DOI: 10.1007/s41669-021-00273-8.


Evidence gaps in economic analyses of hearing healthcare: A systematic review.

Borre E, Diab M, Ayer A, Zhang G, Emmett S, Tucci D EClinicalMedicine. 2021; 35:100872.

PMID: 34027332 PMC: 8129894. DOI: 10.1016/j.eclinm.2021.100872.


A Cost-Benefit Analysis of Hearing Aids, Including the Benefits of Reducing the Symptoms of Dementia.

Brent R Appl Econ. 2019; 51(28):3091-3103.

PMID: 31631893 PMC: 6800143. DOI: 10.1080/00036846.2018.1564123.